Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Nov;116(5):2531–2537. doi: 10.1111/j.1476-5381.1995.tb15106.x

Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia.

Y Noda 1, K Yamada 1, H Furukawa 1, T Nabeshima 1
PMCID: PMC1909055  PMID: 8581295

Abstract

1. Immobility induced by forced swimming is well known as an animal model of depression. To develop an animal model for the negative symptoms of schizophrenia, in particular the depressive symptoms, the effect of phencyclidine (PCP) on immobility in the forced swimming test was investigated in mice, since PCP produces such negative symptoms in humans. 2. Repeated treatment with PCP (10 mg kg-1 day-1, s.c., once a day for 14 days) prolonged the immobility time in the forced swimming test 24 h after the final injection compared with saline treatment; the effect was not obtained by single or 5 treatments with PCP (10 mg kg-1, s.c.), or by repeated treatment with methamphetamine (0.5 and 1 mg kg-1 day-1, s.c., once a day for 14 days). 3. The enhancing effect of PCP (10 mg kg-1 day-1, s.c.) on the immobility persisted for at least 21 days after the withdrawal of the drug. 4. Haloperidol (0.3 and 1 mg kg-1, p.o.), ritanserin (3 and 10 mg kg-1, p.o.), risperidone (0.1-1 mg kg-1, p.o.), and clozapine (3 and 10 mg kg-1, p.o.) failed to attenuate the immobility induced by the forced swimming in mice repeatedly treated with saline when the drugs were administered 1 h before the forced swimming test. However, ritanserin (30 mg kg-1) and clozapine (30 mg kg-1) did attenuate this immobility. 5. The enhancing effect of PCP on the immobility was attenuated by ritanserin (3 and 10 mg kg-1, p.o.), risperidone (0.3 mg kg-1, p.o.), and clozapine (3 and 10 mg kg-1, p.o.), whereas haloperidol (0.3 and 1 mg kg-1, p.o.) had no effect. 6. These results suggest that the enhancement of immobility in the forced swimming test brought about by repeated PCP treatment could be used as a model of the negative symptoms, particularly the depression, of schizophrenia. This effect of PCP appeared to be mediated, at least in part, via 5-HT2A receptors.

Full text

PDF
2531

Images in this article

2534Figure 6
on p.2534
2534Figure 7
on p.2534

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen N. C. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry. 1990;24:73–88. doi: 10.1159/000418013. [DOI] [PubMed] [Google Scholar]
  2. BRADY J. V. Assessment of drug effects on emotional behavior. Science. 1956 Jun 8;123(3206):1033–1034. doi: 10.1126/science.123.3206.1033. [DOI] [PubMed] [Google Scholar]
  3. Barnes T. R., Curson D. A., Liddle P. F., Patel M. The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry. 1989 Apr;154:486–491. doi: 10.1192/bjp.154.4.486. [DOI] [PubMed] [Google Scholar]
  4. Bleich A., Brown S. L., Kahn R., van Praag H. M. The role of serotonin in schizophrenia. Schizophr Bull. 1988;14(2):297–315. doi: 10.1093/schbul/14.2.297. [DOI] [PubMed] [Google Scholar]
  5. Boyer P., Lecrubier Y., Puech A. J. Treatment of positive and negative symptoms: pharmacologic approaches. Mod Probl Pharmacopsychiatry. 1990;24:152–174. doi: 10.1159/000418016. [DOI] [PubMed] [Google Scholar]
  6. Cancela L. M., Rossi S., Molina V. A. Effect of different restraint schedules on the immobility in the forced swim test: modulation by an opiate mechanism. Brain Res Bull. 1991 May;26(5):671–675. doi: 10.1016/0361-9230(91)90159-h. [DOI] [PubMed] [Google Scholar]
  7. Castelão J. F., Ferreira L., Gelders Y. G., Heylen S. L. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res. 1989 Jul-Oct;2(4-5):411–415. doi: 10.1016/0920-9964(89)90034-0. [DOI] [PubMed] [Google Scholar]
  8. Ceulemans D. L., Gelders Y. G., Hoppenbrouwers M. L., Reyntjens A. J., Janssen P. A. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl) 1985;85(3):329–332. doi: 10.1007/BF00428197. [DOI] [PubMed] [Google Scholar]
  9. Contreras P. C., Contreras M. L., O'Donohue T. L., Lair C. C. Biochemical and behavioral effects of sigma and PCP ligands. Synapse. 1988;2(3):240–243. doi: 10.1002/syn.890020311. [DOI] [PubMed] [Google Scholar]
  10. Contreras P. C., DiMaggio D. A., O'Donohue T. L. An endogenous ligand for the sigma opioid binding site. Synapse. 1987;1(1):57–61. doi: 10.1002/syn.890010108. [DOI] [PubMed] [Google Scholar]
  11. Contreras P. C., Rice K. C., Jacobson A. E., O'Donohue T. L. Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions. Eur J Pharmacol. 1986 Feb 11;121(1):9–18. doi: 10.1016/0014-2999(86)90386-9. [DOI] [PubMed] [Google Scholar]
  12. Davidson J., Miller R., Wingfield M., Zung W., Dren A. T. The first clinical study of BW-234U in schizophrenia. Psychopharmacol Bull. 1982 Oct;18(4):173–176. [PubMed] [Google Scholar]
  13. Dickerson F. B., Ringel N. B., Boronow J. J. Neuropsychological deficits in chronic schizophrenics. Relationship with symptoms and behavior. J Nerv Ment Dis. 1991 Dec;179(12):744–749. doi: 10.1097/00005053-199112000-00006. [DOI] [PubMed] [Google Scholar]
  14. Fenton W. S., McGlashan T. H. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry. 1992 Mar;49(3):179–184. doi: 10.1001/archpsyc.1992.01820030011002. [DOI] [PubMed] [Google Scholar]
  15. Gelders Y. G. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry Suppl. 1989 Jul;(5):33–36. [PubMed] [Google Scholar]
  16. Gelenberg A. J., Doller J. C. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry. 1979 May;40(5):238–240. [PubMed] [Google Scholar]
  17. Harlow H. F., Suomi S. J. Induced depression in monkeys. Behav Biol. 1974 Nov;12(3):273–296. doi: 10.1016/s0091-6773(74)91475-8. [DOI] [PubMed] [Google Scholar]
  18. Hirschowitz J., Hitzemann R., Burr G., Schwartz A. A new approach to dose reduction in chronic schizophrenia. Neuropsychopharmacology. 1991 Sep;5(2):103–113. [PubMed] [Google Scholar]
  19. Hurlbut K. M. Drug-induced psychoses. Emerg Med Clin North Am. 1991 Feb;9(1):31–52. [PubMed] [Google Scholar]
  20. Janssen P. A., Niemegeers C. J., Awouters F., Schellekens K. H., Megens A. A., Meert T. F. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988 Feb;244(2):685–693. [PubMed] [Google Scholar]
  21. Javitt D. C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry. 1987;9(1):12–35. [PubMed] [Google Scholar]
  22. Javitt D. C., Zukin S. R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 Oct;148(10):1301–1308. doi: 10.1176/ajp.148.10.1301. [DOI] [PubMed] [Google Scholar]
  23. Javitt D. C., Zukin S. R. The role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatry Clin Neurosci. 1990 Winter;2(1):44–52. doi: 10.1176/jnp.2.1.44. [DOI] [PubMed] [Google Scholar]
  24. Javitt D. C., Zylberman I., Zukin S. R., Heresco-Levy U., Lindenmayer J. P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994 Aug;151(8):1234–1236. doi: 10.1176/ajp.151.8.1234. [DOI] [PubMed] [Google Scholar]
  25. Katz R. J., Roth K. A., Carroll B. J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci Biobehav Rev. 1981 Summer;5(2):247–251. doi: 10.1016/0149-7634(81)90005-1. [DOI] [PubMed] [Google Scholar]
  26. Kennett G. A., Dickinson S. L., Curzon G. Enhancement of some 5-HT-dependent behavioural responses following repeated immobilization in rats. Brain Res. 1985 Mar 25;330(2):253–263. doi: 10.1016/0006-8993(85)90684-5. [DOI] [PubMed] [Google Scholar]
  27. Kitaichi K., Yamada K., Hasegawa T., Furukawa H., Nabeshima T. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. Jpn J Pharmacol. 1994 Oct;66(2):181–189. doi: 10.1254/jjp.66.181. [DOI] [PubMed] [Google Scholar]
  28. Knights A., Hirsch S. R. "Revealed" Depression and drug treatment for schizophrenia. Arch Gen Psychiatry. 1981 Jul;38(7):806–811. doi: 10.1001/archpsyc.1981.01780320086010. [DOI] [PubMed] [Google Scholar]
  29. Kukla F., Gold R. Schizophrene Minussymptomatik und ihre Erfassungsmethodik. Fortschr Neurol Psychiatr. 1991 Feb;59(2):60–66. doi: 10.1055/s-2007-1000680. [DOI] [PubMed] [Google Scholar]
  30. LUBY E. D., COHEN B. D., ROSENBAUM G., GOTTLIEB J. S., KELLEY R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry. 1959 Mar;81(3):363–369. doi: 10.1001/archneurpsyc.1959.02340150095011. [DOI] [PubMed] [Google Scholar]
  31. Largent B. L., Wikström H., Snowman A. M., Snyder S. H. Novel antipsychotic drugs share high affinity for sigma receptors. Eur J Pharmacol. 1988 Oct 18;155(3):345–347. doi: 10.1016/0014-2999(88)90527-4. [DOI] [PubMed] [Google Scholar]
  32. Levinson D. F. Pharmacologic treatment of schizophrenia. Clin Ther. 1991 May-Jun;13(3):326–352. [PubMed] [Google Scholar]
  33. Lieberman J. A., Kane J. M., Johns C. A. Clozapine: guidelines for clinical management. J Clin Psychiatry. 1989 Sep;50(9):329–338. [PubMed] [Google Scholar]
  34. Lipska B. K., Jaskiw G. E., Weinberger D. R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology. 1993 Aug;9(1):67–75. doi: 10.1038/npp.1993.44. [DOI] [PubMed] [Google Scholar]
  35. Luisada P. V., Brown B. I. Clinical management of the phencyclidine psychosis. Clin Toxicol. 1976;9(4):539–545. doi: 10.3109/15563657608988155. [DOI] [PubMed] [Google Scholar]
  36. McGlashan T. H., Carpenter W. T., Jr An investigation of the postpsychotic depressive syndrome. Am J Psychiatry. 1976 Jan;133(1):14–19. doi: 10.1176/ajp.133.1.14. [DOI] [PubMed] [Google Scholar]
  37. Meltzer H. Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991;17(2):263–287. doi: 10.1093/schbul/17.2.263. [DOI] [PubMed] [Google Scholar]
  38. Molina V. A., Heyser C. J., Spear L. P. Chronic variable stress or chronic morphine facilitates immobility in a forced swim test: reversal by naloxone. Psychopharmacology (Berl) 1994 Apr;114(3):433–440. doi: 10.1007/BF02249333. [DOI] [PubMed] [Google Scholar]
  39. Murua V. S., Molina V. A. Antidepressants reduce inactivity during both inescapable shock administration and shuttle-box testing. Eur J Pharmacol. 1991 Nov 5;204(2):187–192. doi: 10.1016/0014-2999(91)90704-t. [DOI] [PubMed] [Google Scholar]
  40. Nabeshima T., Hiramatsu M., Kameyama T. Phencyclidine-induced stereotyped behaviors after injection of morphine and N-allylnormetazocine (SKF 10,047) in rats. Pharmacol Biochem Behav. 1986 Jun;24(6):1629–1634. doi: 10.1016/0091-3057(86)90497-1. [DOI] [PubMed] [Google Scholar]
  41. Nabeshima T., Ishikawa K., Yamaguchi K., Furukawa H., Kameyama T. Phencyclidine-induced head-weaving observed in mice after ritanserin treatment. Eur J Pharmacol. 1987 Jul 9;139(2):171–178. doi: 10.1016/0014-2999(87)90249-4. [DOI] [PubMed] [Google Scholar]
  42. Nabeshima T., Noda Y., Yamaguchi K., Ishikawa K., Furukawa H., Kameyama T. Acute and chronic phencyclidine administration changes serotonin receptors in rat brain. Eur J Pharmacol. 1985 Feb 12;109(1):129–130. doi: 10.1016/0014-2999(85)90550-3. [DOI] [PubMed] [Google Scholar]
  43. Nabeshima T., Tohyama K., Noda A., Maeda Y., Hiramatsu M., Harrer S. M., Kameyama T., Furukawa H., Jacobson A. E., Rice K. C. Effects of metaphit on phencyclidine and serotonin2 receptors. Neurosci Lett. 1989 Jul 31;102(2-3):303–308. doi: 10.1016/0304-3940(89)90096-7. [DOI] [PubMed] [Google Scholar]
  44. Nabeshima T., Yamaguchi K., Hiramatsu M., Amano M., Furukawa H., Kameyama T. Serotonergic involvement in phencyclidine-induced behaviors. Pharmacol Biochem Behav. 1984 Sep;21(3):401–408. doi: 10.1016/s0091-3057(84)80102-1. [DOI] [PubMed] [Google Scholar]
  45. Noda Y., Kurumiya S., Miura Y., Oka M. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther. 1993 May;265(2):745–751. [PubMed] [Google Scholar]
  46. Ogawa S., Okuyama S., Araki H., Otomo S. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur J Pharmacol. 1994 Sep 22;263(1-2):9–15. doi: 10.1016/0014-2999(94)90517-7. [DOI] [PubMed] [Google Scholar]
  47. Oka M., Noda Y., Ochi Y., Furukawa K., Une T., Kurumiya S., Hino K., Karasawa T. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther. 1993 Jan;264(1):158–165. [PubMed] [Google Scholar]
  48. Peralta V., de Leon J., Cuesta M. J. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry. 1992 Sep;161:335–343. doi: 10.1192/bjp.161.3.335. [DOI] [PubMed] [Google Scholar]
  49. Porsolt R. D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978 Feb 15;47(4):379–391. doi: 10.1016/0014-2999(78)90118-8. [DOI] [PubMed] [Google Scholar]
  50. Porsolt R. D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327–336. [PubMed] [Google Scholar]
  51. Porsolt R. D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977 Apr 21;266(5604):730–732. doi: 10.1038/266730a0. [DOI] [PubMed] [Google Scholar]
  52. Płaźnik A., Tamborska E., Hauptmann M., Bidziński A., Kostowski W. Brain neurotransmitter systems mediating behavioral deficits produced by inescapable shock treatment in rats. Brain Res. 1988 Apr 26;447(1):122–132. doi: 10.1016/0006-8993(88)90972-9. [DOI] [PubMed] [Google Scholar]
  53. Rainey J. M., Jr, Crowder M. K. Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry. 1975 Oct;132(10):1076–1078. doi: 10.1176/ajp.132.10.1076. [DOI] [PubMed] [Google Scholar]
  54. Reynolds G. P. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci. 1992 Mar;13(3):116–121. doi: 10.1016/0165-6147(92)90041-4. [DOI] [PubMed] [Google Scholar]
  55. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol. 1995 Jan;6(1):55–65. [PubMed] [Google Scholar]
  56. Sanger D. J., Joly D. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice. Psychopharmacology (Berl) 1991;104(1):27–34. doi: 10.1007/BF02244550. [DOI] [PubMed] [Google Scholar]
  57. Sayed Y., Garrison J. M. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs--a review. Psychopharmacol Bull. 1983 Spring;19(2):283–288. [PubMed] [Google Scholar]
  58. Sonders M. S., Keana J. F., Weber E. Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action. Trends Neurosci. 1988 Jan;11(1):37–40. doi: 10.1016/0166-2236(88)90048-3. [DOI] [PubMed] [Google Scholar]
  59. Stern M. J., Pillsbury J. A., Sonnenberg S. M. Postpsychotic depression in schizophrenics. Compr Psychiatry. 1972 Nov-Dec;13(6):591–598. doi: 10.1016/0010-440x(72)90060-0. [DOI] [PubMed] [Google Scholar]
  60. Su T. P. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther. 1982 Nov;223(2):284–290. [PubMed] [Google Scholar]
  61. Tam S. W., Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci U S A. 1984 Sep;81(17):5618–5621. doi: 10.1073/pnas.81.17.5618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Troisi A., Pasini A., Bersani G., Di Mauro M., Ciani N. Negative symptoms and visual behavior in DSM-III-R prognostic subtypes of schizophreniform disorder. Acta Psychiatr Scand. 1991 May;83(5):391–394. doi: 10.1111/j.1600-0447.1991.tb05562.x. [DOI] [PubMed] [Google Scholar]
  63. Van Dijken H. H., Van der Heyden J. A., Mos J., Tilders F. J. Inescapable footshocks induce progressive and long-lasting behavioural changes in male rats. Physiol Behav. 1992 Apr;51(4):787–794. doi: 10.1016/0031-9384(92)90117-k. [DOI] [PubMed] [Google Scholar]
  64. Volkow N. D., Fowler J. S. Neuropsychiatric disorders: investigation of schizophrenia and substance abuse. Semin Nucl Med. 1992 Oct;22(4):254–267. doi: 10.1016/s0001-2998(05)80120-5. [DOI] [PubMed] [Google Scholar]
  65. Wadworth A. N., Heel R. C. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs. 1990 Dec;40(6):863–879. doi: 10.2165/00003495-199040060-00008. [DOI] [PubMed] [Google Scholar]
  66. Wilmot C. A., Szczepanik A. M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res. 1989 May 22;487(2):288–298. doi: 10.1016/0006-8993(89)90833-0. [DOI] [PubMed] [Google Scholar]
  67. Yamaguchi K., Nabeshima T., Kameyama T. Role of dopaminergic and serotonergic neuronal systems in the prefrontal cortex of rats in phencyclidine-induced behaviors. J Pharmacobiodyn. 1986 Dec;9(12):987–996. doi: 10.1248/bpb1978.9.987. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES